References
- Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–805
- Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: Time for a new “gold standard”. Clin Infect Dis 2003; 37: 415–425
- Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147–1201
- Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–615
- Lin S-W, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366
- Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, practices, and outcomes. Medicine (Baltimore) 2000; 79: 250–260
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
- Boucher, HW. Voriconazole FDA application for licensing. www.fda.gov/ohrms/dockets/ac/01/slides/3792s2_01_3-Pfizer-boucher/index.htm.
- Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396
- Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325–1330
- Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964–972
- Anaissie, EJ, White, MH, Ozun, O, , et al. Amphotericin B lipid complex vs amphotericin B for treatment of invasive candidiasis: a prospective, randomized multicenter trial. In:. Program and abstracts of the 35th ICAAC San Francisco, September 18, 1995. abstr.
- Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029
- Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764–771
- Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234
- Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402